Cargando…
Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma
BACKGROUND: This phase II trial was designed to assess the response rate, survival benefits and toxicity profile of temozolomide, and brain reirradiation using conformal radiotherapy (CRT) for recurrent grade II brain glioma. Between February 2006 and June 2009, 18 patients with recurrent low grade...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elmer Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649814/ https://www.ncbi.nlm.nih.gov/pubmed/29147389 http://dx.doi.org/10.14740/wjon838w |